The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I and pharmacokinetic study of sorafenib in Kaposi sarcoma.
Thomas S. Uldrick
No relevant relationships to disclose
Kathleen Wyvill
No relevant relationships to disclose
Cody Peer
No relevant relationships to disclose
Mark Niccolo Polizzotto
No relevant relationships to disclose
Deirdre O'Mahony
No relevant relationships to disclose
Wendy Bernstein
No relevant relationships to disclose
Karen Aleman
No relevant relationships to disclose
Seth M. Steinberg
No relevant relationships to disclose
David J. Venzon
No relevant relationships to disclose
Stefania Pittaluga
No relevant relationships to disclose
Richard F. Little
No relevant relationships to disclose
William Douglas Figg
No relevant relationships to disclose
Robert Yarchoan
No relevant relationships to disclose